Cystic Fibrosis

3 articles published between June 11, 2026 and October 18, 2026.

WHAT THE STUDY ACTUALLY SAYS

An inhaled RNA drug showed first signs of benefit in a rare cystic fibrosis mutation

In a 17-person phase 2a trial, once-weekly inhaled SPL84 lifted lung function in up to 70% of treated patients with the 3849+10 kb C→T mutation — a first reported clinical signal for an RNA-targeted inhaled therapy.

3 min read

WHAT THE STUDY ACTUALLY SAYS

A chemically edited tRNA, delivered to the lung, read through a cystic fibrosis stop codon

Suppressor tRNAs have been a promising idea for nonsense mutations for years, held back by weak activity and delivery. A Science paper reports one chemical tweak and one redesigned nanoparticle.

3 min read

WHAT THE STUDY ACTUALLY SAYS

Europe's cystic fibrosis population became mostly adult in a single decade

Data from 20 European countries covering 2014 to 2024 tracks lung function, nutrition and infection through the arrival of triple modulator therapy — and the new complications arriving with age.

4 min read

This page indexes this newspaper’s reporting on Cystic Fibrosis. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.